Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.
News|Articles|October 15, 2025
Sponsored: The Teva Biosimilars Trend Report
Advertisement
The Teva Biosimilars Trend Report: Perspectives from Managed Care, Providers & Employers.
Second edition.
Read the full report below:
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Christine Johnston on why biosimilars are losing formulary ground
2
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
3
McKesson, private equity firm buy home infusion company, Option Care Health
4
Medicare Advantage needs fixing. Here are 3 feasible repairs
5